Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

(2015) G. Gibney et al.   EUROPEAN JOURNAL OF CANCER

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

(2014) Zuzana Berrong et al.   Journal for ImmunoTherapy of Cancer

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

(2014) Minghui Li et al.   Journal for ImmunoTherapy of Cancer

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate

(2010) A. J. Muller et al.   CANCER RESEARCH

Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease

(2010) D. Favre et al.   Science Translational Medicine

Interferon-γ-Responsive Nonhematopoietic Cells Regulate the Immune Response to Mycobacterium tuberculosis

(2009) Ludovic Desvignes et al.   IMMUNITY

Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival

(2008) K. Ino et al.   CLINICAL CANCER RESEARCH

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer

(2008) Chantal Feder-Mengus et al.   EUROPEAN JOURNAL OF CANCER

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

(2008) M. E.D. Chamuleau et al.   HAEMATOLOGICA

Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection

(2008) Agnes Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS